Adicet Bio, Inc. (ACET)
NASDAQ: ACET · Real-Time Price · USD
4.040
-0.240 (-5.61%)
Oct 23, 2026, 1:05 PM EDT - Market open
Adicet Bio Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| - | - | - | - | 24.99 | 9.73 | |
Revenue Growth | - | - | - | - | 156.83% | -45.65% |
Gross Profit | - | - | - | - | 24.99 | 9.73 |
Selling, General & Admin | 19.88 | 22.99 | 28.29 | 26.53 | 26.3 | 22.22 |
Research & Development | 83.83 | 99.13 | 99.32 | 106.04 | 71.25 | 47.75 |
Operating Expenses | 103.71 | 122.11 | 127.62 | 132.58 | 97.54 | 69.97 |
Operating Income | -103.71 | -122.11 | -127.62 | -132.58 | -72.55 | -60.24 |
Interest Expense | -0.08 | -0.04 | -0 | -0.03 | -0.08 | -0.18 |
Interest & Investment Income | 5.21 | 5.78 | 10.71 | 9.98 | 3.76 | 0.09 |
Other Non Operating Income (Expenses) | -0.25 | -0.43 | -0.22 | -0.57 | -0.92 | -0.61 |
EBT Excluding Unusual Items | -98.83 | -116.8 | -117.12 | -123.2 | -69.79 | -60.93 |
Impairment of Goodwill | - | - | - | -19.46 | - | - |
Asset Writedown | - | - | - | - | - | -1.19 |
Pretax Income | -98.83 | -116.8 | -117.12 | -142.66 | -69.79 | -62.12 |
Income Tax Expense | 0.14 | - | - | - | - | -0.13 |
Net Income | -98.97 | -116.8 | -117.12 | -142.66 | -69.79 | -62 |
Net Income to Common | -98.97 | -116.8 | -117.12 | -142.66 | -69.79 | -62 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 9 | 7 | 5 | 3 | 3 | 2 |
Shares Outstanding (Diluted) | 9 | 7 | 5 | 3 | 3 | 2 |
Shares Change | 65.16% | 25.49% | 104.14% | 4.78% | 32.72% | 322.85% |
EPS (Basic) | -10.52 | -16.95 | -21.33 | -53.03 | -27.18 | -32.05 |
EPS (Diluted) | -10.52 | -16.95 | -21.33 | -53.03 | -27.18 | -32.05 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -84.97 | -96.98 | -93.5 | -98.18 | -61.55 | -64.1 |
Free Cash Flow Per Share | -9.03 | -14.07 | -17.02 | -36.50 | -23.97 | -33.13 |
Gross Margin | - | - | - | - | 100.00% | 100.00% |
Operating Margin | - | - | - | - | -290.32% | -619.15% |
Profit Margin | - | - | - | - | -279.27% | -637.19% |
Free Cash Flow Margin | - | - | - | - | -246.29% | -658.77% |
EBITDA | -98.12 | -115.73 | -121.15 | -126.48 | -69.98 | -58.71 |
EBITDA Margin | - | - | - | - | -280.02% | - |
D&A For EBITDA | 5.59 | 6.38 | 6.47 | 6.1 | 2.58 | 1.54 |
EBIT | -103.71 | -122.11 | -127.62 | -132.58 | -72.55 | -60.24 |
EBIT Margin | - | - | - | - | -290.32% | - |